Rhythm Pharmaceuticals, Inc. (RYTM) Expected to Beat Earnings Estimates: Should You Buy?Zacks Investment Research • 02/19/26
Rhythm Pharmaceuticals to Report Fourth Quarter and Full Year 2025 Financial Results on Thursday, February 26, 2026GlobeNewsWire • 02/17/26
Rhythm Pharmaceuticals Announces Participation in Upcoming Guggenheim Biotech SummitGlobeNewsWire • 02/05/26
Rhythm Pharmaceuticals Announces Preliminary, Unaudited Fourth Quarter and Full Year 2025 Net Product Revenues and Upcoming MilestonesGlobeNewsWire • 01/09/26
Rhythm: PWS Signal, HO Speed Bump, And The Case For A Rare-Obesity BlockbusterSeeking Alpha • 12/11/25
Rhythm Pharmaceuticals, Inc. (RYTM) Discusses Preliminary Phase II Data of Setmelanotide in Prader-Willi Syndrome and Next Steps TranscriptSeeking Alpha • 12/11/25
Rhythm Pharmaceuticals Announces Preliminary Data from Exploratory Phase 2 Trial that showed Setmelanotide Demonstrated Positive Efficacy Signal in Prader-Willi SyndromeGlobeNewsWire • 12/11/25
Rhythm Pharmaceuticals to Announce Preliminary Data from Exploratory Phase 2 Trial Evaluating Setmelanotide in Prader-Willi SyndromeGlobeNewsWire • 12/10/25
Rhythm: Maintaining Strong Buy On Acquired Hypothalamic Obesity Drug ProgressSeeking Alpha • 11/25/25
Rhythm Pharmaceuticals Announces Presentation of Four Datasets at ObesityWeek® 2025GlobeNewsWire • 11/10/25
Rythm Pharmaceuticals' (RYTM) Chief Technical Officer Sells 9,748 Shares for $1.1 MillionThe Motley Fool • 11/08/25
Rhythm Pharmaceuticals Announces FDA Extension of Review Period for IMCIVREE® (setmelanotide) for Patients with Acquired Hypothalamic ObesityGlobeNewsWire • 11/07/25
Rhythm Pharmaceuticals Announces Public Reimbursement for IMCIVREE® (setmelanotide) in Canada in Five Provinces and Under the Federal Non-Insured Health Benefits ProgramGlobeNewsWire • 11/05/25
Rhythm Pharmaceuticals, Inc. (RYTM) Reports Q3 Loss, Tops Revenue EstimatesZacks Investment Research • 11/04/25
Rhythm Pharmaceuticals Reports Third Quarter 2025 Financial Results and Business UpdateGlobeNewsWire • 11/04/25
Rhythm Pharmaceuticals to Report Third Quarter 2025 Financial Results on Tuesday, November 4, 2025GlobeNewsWire • 10/21/25